Additional Information About New Drugs’ Dangers
We received multiple requests for additional information after we published our last article describing new drugs’ dangers based on recent developments related to hepatitis C drugs. Accordingly, we have written another brief article providing additional information reflecting why all health plan administrators should exclude – or limit – coverage of many new drugs.
Read More
Protect Your Plan Beneficiaries From New Drugs’ Dangers
The latest FDA Black Box Warning about hepatitis C treatments demonstrates why it’s imperative that your Plan implement methods for protecting your beneficiaries against the dangers of new drugs.
After all, more than three years after the FDA approved the first of eight new hep C treatments, the FDA has just issued yet another warning about a newly discovered danger related to these drugs.
Read More